CytomX Therapeutics CTMX Income from Continuing Ops
Income from Continuing Ops at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerBasicShare.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's income from continuing ops.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's income from continuing ops?
- CytomX Therapeutics (CTMX) reported income from continuing ops of -$0.10 in Q1 2026.
- How has CytomX Therapeutics's income from continuing ops changed year-over-year?
- CytomX Therapeutics's income from continuing ops decreased by 137.0% year-over-year, from $0.27 to -$0.10.
- What is the long-term trend for CytomX Therapeutics's income from continuing ops?
- Over 3 years (2021 to 2025), CytomX Therapeutics's income from continuing ops has grown at a -71.9% compound annual growth rate (CAGR), from -$1.80 to -$0.04.
- What does income from continuing ops mean?
- Net income from business operations that are expected to continue, excluding gains or losses from discontinued segments. The best measure of ongoing earning power.